鼻腔恶性黑色素瘤术后复发1例报道及文献复习
Case Report and Literature Review of a Recurrence of Nasal Malignant Melanoma after Surgery
DOI: 10.12677/acm.2024.1482353, PDF,   
作者: 张碧琳, 黄志凤, 郭 甜, 陈 森：西安医学院研究生工作部，陕西 西安；杨怡萍*：陕西省肿瘤医院放疗三科，陕西 西安
关键词: 鼻腔及鼻窦恶性黑色素瘤；术后复发；综合治疗方案；Nasal and Paranasal Malignant Melanoma； Postoperative Recurrence； Comprehensive Treatment Strategy
摘要: 鼻腔及鼻窦恶性黑色素瘤来源于鼻腔黏膜的树状突黑色素细胞，其发生率占头颈部恶性肿瘤的2%左右。该类肿瘤因恶性程度高，易复发和转移，由此预后较差。且大多数共识中未提及鼻腔黑色素瘤术后复发的治疗方案，所以如何选择适当的治疗方法，最大限度提高鼻腔及鼻窦恶性黑色素瘤患者的生存期及生活质量一直是临床的难点。本例为一例鼻腔黏膜恶性黑色素瘤术后复发的患者，结合文献复习，对该疾病初诊疗进行回顾分析，以期为此类患者的临床诊疗提供参考。
Abstract: Nasal and paranasal malignant melanomas originate from dendritic melanocytes in the nasal mucosa, accounting for approximately 2% of malignant tumors in the head and neck region. These tumors are highly malignant, prone to recurrence and metastasis, resulting in poor prognosis. Current consensus guidelines often lack detailed treatment protocols for recurrent nasal melanoma post-surgery. Thus, selecting the most appropriate treatment to maximize survival and quality of life for patients with nasal and paranasal malignant melanoma remains a clinical challenge. This report details a case of recurrent nasal mucosal malignant melanoma following surgery. A review of the literature is conducted to analyze initial diagnosis and treatment strategies, providing clinical insights for managing similar cases.
文章引用：张碧琳, 黄志凤, 郭甜, 陈森, 杨怡萍. 鼻腔恶性黑色素瘤术后复发1例报道及文献复习[J]. 临床医学进展, 2024, 14(8): 1299-1303. https://doi.org/10.12677/acm.2024.1482353

参考文献

[1] 王稼祥, 斯璐. 2023年度黑色素瘤药物治疗研究进展[J]. 肿瘤综合治疗电子杂志, 2024, 10(2): 54-58.
[2] Bobos, M. (2021) Histopathologic Classification and Prognostic Factors of Melanoma: A 2021 Update. Italian Journal of Dermatology and Venereology, 156, 300-321. [Google Scholar] [CrossRef] 
[3] 吴娜明, 李军, 陶娟. 恶性黑色素瘤的诊断热点[J]. 诊断学理论与实践, 2023, 22(3): 215-220.
[4] Rawson, R.V., Wilmott, J.S. and Scolyer, R.A. (2021) Mucosal Melanoma: A Review Emphasizing the Molecular Landscape and Implications for Diagnosis and Management. Surgical Pathology Clinics, 14, 293-307. [Google Scholar] [CrossRef] [PubMed]
[5] 常雯, 吴莉, 韩丹. 鼻腔鼻窦恶性黑色素瘤的影像学研究进展[J]. 临床耳鼻咽喉头颈外科杂志, 2018, 32(12): 960-962.
[6] Olla, D. and Neumeister, M.W. (2021) Mucosal Melanoma. Clinics in Plastic Surgery, 48, 707-711. [Google Scholar] [CrossRef] [PubMed]
[7] Nenclares, P., Ap, D.D. and Bagwan, I. (2020) Head and Neck Mucosal Melanoma: The United Kingdom National Guidelines. European Journal of Cancer, 138, 11-18. [Google Scholar] [CrossRef] [PubMed]
[8] Zhang, J., Tian, H. and Mao, L. (2024) Treatment of Acral and Mucosal Melanoma: Current and Emerging Targeted Therapies. Critical Reviews in Oncology/Hematology, 193, Article 104221. [Google Scholar] [CrossRef] [PubMed]
[9] Zhang, S., Zhang, J. and Guo, J. (2022) Evolving Treatment Approaches to Mucosal Melanoma. Current Oncology Reports, 24, 1261-1271. [Google Scholar] [CrossRef] [PubMed]
[10] Pandrangi, V.C., Mace, J.C. and Abiri, A. (2023) Recurrence Patterns among Patients with Sinonasal Mucosal Melanoma: A Multi-Institutional Study. International Forum of Allergy & Rhinology, 13, 2156-2164. [Google Scholar] [CrossRef] [PubMed]
[11] Lian, B., Li, Z. and Wu, N. (2024) Phase II Clinical Trial of Neoadjuvant Anti-PD-1 (Toripalimab) Combined with Axitinib in Resectable Mucosal Melanoma. Annals of Oncology, 35, 211-220. [Google Scholar] [CrossRef] [PubMed]
[12] Ong, C.V. and Samlowski, W. (2024) Neoadjuvant Ipilimumab Plus Nivolumab Therapy as a Potential Organ Preservation Strategy in Mucosal Melanoma: Case Report. Frontiers in Oncology, 14, Article 1301424. [Google Scholar] [CrossRef] [PubMed]
[13] Krueger, O., Eisenburger, R. and Tasdogan, A. (2024) Case Report: Durable Complete Response of a Mucosal Melanoma of the Rectum after Neoadjuvant Immunotherapy with Ipilimumab Plus Nivolumab. Frontiers in Immunology, 15, Article 1369190. [Google Scholar] [CrossRef] [PubMed]
[14] Lund, V.J. (2020) Sinonasal Malignant Melanoma. In: Nicolai, P. and Bradley, P.J., Eds., Anterior Skull Base Tumors, Karger Publishers, 185-196. [Google Scholar] [CrossRef] [PubMed]
[15] Sahovaler, A., Ziai, H. and Cardemil, F. (2021) Importance of Margins, Radiotherapy, and Systemic Therapy in Mucosal Melanoma of the Head and Neck. Laryngoscope, 131, 2269-2276. [Google Scholar] [CrossRef] [PubMed]
[16] Tang, A., Taori, S. and Dang, S. (2024) Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review. Otolaryngology-Head and Neck Surgery, 171, 368-380. [Google Scholar] [CrossRef] [PubMed]
[17] Nenclares, P. and Harrington, K.J. (2022) Management of Head and Neck Mucosal Melanoma. Oral and Maxillofacial Surgery Clinics, 34, 299-314. [Google Scholar] [CrossRef] [PubMed]
[18] 田惠春, 张佳冉, 斯璐. 2023年CSCO黑色素瘤诊疗指南更新要点解读[J]. 实用肿瘤杂志, 2023, 38(6): 509-512.
[19] Tzelnick, S., Levin, E.G. and Yacobi, D. (2022) Recurrence Patterns and Efficacy of Surveillance Modalities for Sinonasal Malignancies. American Journal of Rhinology & Allergy, 36, 473-479. [Google Scholar] [CrossRef] [PubMed]
[20] Bhave, P., Hong, A. and Lo, S.N. (2023) Efficacy and Toxicity of Adjuvant Radiotherapy in Recurrent Melanoma after Adjuvant Immunotherapy. The Journal for ImmunoTherapy of Cancer, 11, e006629. [Google Scholar] [CrossRef] [PubMed]
[21] Li, S., Wu, X. and Yan, X. (2022) Toripalimab Plus Axitinib in Patients with Metastatic Mucosal Melanoma: 3-Year Survival Update and Biomarker Analysis. The Journal for ImmunoTherapy of Cancer, 10, e004036. [Google Scholar] [CrossRef] [PubMed]

为你推荐